- 関
- antilipemic agent、antilipemic drug、hypolipidemic、hypolipidemic agent、hypolipidemic drug、hypolipidemics、lipid-lowering drug
WordNet
- a substance that exerts some force or effect
- a businessman who buys or sells for another in exchange for a commission (同)factor, broker
- any agent or representative of a federal agency or bureau (同)federal agent
- a representative who acts on behalf of other persons or organizations
- an active and efficient cause; capable of producing a certain effect; "their research uncovered new disease agents"
- how long something has existed; "it was replaced because of its age"
- a time of life (usually defined in years) at which some particular qualification or power arises; "she was now of school age"; "tall for his eld" (同)eld
- begin to seem older; get older; "The death of his wife caused him to age fast"
- make older; "The death of his child aged him tremendously"
- (botany) either of the two parts of a bilabiate corolla or calyx
- either the outer margin or the inner margin of the aperture of a gastropods shell
- either of two fleshy folds of tissue that surround the mouth and play a role in speaking
- the act of causing something to move to a lower level (同)letting down
- the act of causing to become less
- an oily organic compound insoluble in water but soluble in organic solvents; essential structural component of living cells (along with proteins and carbohydrates) (同)lipide, lipoid
PrepTutorEJDIC
- 『代理人』;周旋人 / 働き(作用)を起こすもの;作用物,薬剤 / (政府機関,特にFBI,CIAなどの)部員,機関員
- 〈U〉(一般に)『年齢』,寿命;〈C〉(個々の)『年齢』,年 / 〈U〉成年(おとなとしての資格・権利を得る年齢;通例18または21歳) / 〈U〉『老齢』;《集合的に》老人たち / 〈U〉(人生の)『一時期』;〈C〉世代(generation) / 〈U〉〈C〉《しばしばA-》(歴史上の)『時代』 / 〈C〉《話》長い間 / 年をとる,ふける;〈物が〉古くなる / 〈年〉'を'とらせる;〈物〉'を'古びさせる
- 〈C〉『くちびる』,口もと / 《複数形で》(発音器官としての)くちびる,口 / 〈U〉《俗》生意気な言葉 / 〈C〉(容器などの)口,へり,縁;(峡谷・火山などの)口 / 〈C〉(植物の)唇弁(しんべん)
- 低くする,低下させる;堕落させる
- (空模様が)険悪な,荒れ模様の / しかめっつらの,(顔つきが)不機嫌な
- 脂質,あぶら
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. スタチン系およびフィブラート系以外の薬剤による脂質低下 lipid lowering with drugs other than statins and fibrates
- 2. 食事または栄養補助食品による脂質低下 lipid lowering with diet or dietary supplements
- 3. 二次予防における脂質（高コレステロール血症を含む）の治療 treatment of lipids including hypercholesterolemia in secondary prevention
- 4. 一次予防における脂質（高コレステロール血症を含む）の治療 treatment of lipids including hypercholesterolemia in primary prevention
- 5. 心血管疾患または糖尿病患者におけるコレステロール低下に関する臨床試験 clinical trials of cholesterol lowering in patients with cardiovascular disease or diabetes
English Journal
- Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
- Fu Q, Li YP, Gao Y, Yang SH, Lu PQ, Jia M, Zhang LR.SourceDepartment of Pharmacology, School of Medicine, Zhengzhou University, 100 Science Road, Zhengzhou, 450001, China.
- European journal of clinical pharmacology.Eur J Clin Pharmacol.2013 Jun;69(6):1269-74. doi: 10.1007/s00228-012-1453-9. Epub 2012 Dec 22.
- PURPOSE: There is significant inter-individual variability in the lipid-lowering effects of atorvastatin and simvastatin. Our goal was to investigate the impact of SLCO1B1 genetic polymorphism on the lipid-lowering effects of atorvastatin and simvastatin.METHODS: We recruited 363 unrelated hyperlipi
- PMID 23263738
- Pharmacological primary and secondary cardiovascular prevention among diabetic patients in a multiethnic general practice population: still room for improvements.
- Tran AT, Straand J, Dalen I, Birkeland KI, Claudi T, Cooper JG, Meyer HE, Jenum AK.AbstractBACKGROUND: Ethnic minority groups have higher prevalence of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). We assessed general practitioners' (GPs') performance with respect to the pharmacological prevention of CVD in patients with T2DM from different ethnic backgrounds in Oslo.
- BMC health services research.BMC Health Serv Res.2013 May 20;13(1):182. [Epub ahead of print]
- BACKGROUND: Ethnic minority groups have higher prevalence of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). We assessed general practitioners' (GPs') performance with respect to the pharmacological prevention of CVD in patients with T2DM from different ethnic backgrounds in Oslo.M
- PMID 23688317
Japanese Journal
- Inhibition of Smooth Muscle Cell Proliferation by Ezetimibe via the Cyclin D1-MAPK Pathway
- Journal of Pharmacological Sciences 125(3), 283-291, 2014
- NAID 130004438638
- Rhabdomyolysis Developing Secondary to Atorvastatin Therapy in a Patient with Liver Cirrhosis
- Internal Medicine 52(7), 823-825, 2013
- NAID 130003365975
- Effect of Probucol on Antioxidant Properties of HDL in Patients with Heterozygous Familial Hypercholesterolemia
- Journal of Atherosclerosis and Thrombosis 19(7), 643-656, 2012
- NAID 130004444622
Related Links
- Clinical and research information on drug-induced liver injury. ... The lipid lowering agents are used to treat hypercholesterolemia and dyslipidemias. These agents are some of the most frequently used medications in the ...
- Lipid-Lowering Agents, Statins: Dosing, Uses, Side Effects, Interactions, Patient Handouts, Pricing and more from Medscape Reference ... Medscape's clinical reference is the most authoritative and accessible point-of-care medical ...
Related Pictures
★リンクテーブル★
| リンク元 | 「高脂血症治療薬」「lipid-lowering drug」「hypolipidemic」「抗高脂血症剤」「antilipemic drug」 |
| 関連記事 | 「agent」「lowering」「age」「lip」 |
「高脂血症治療薬」
| Cho | TG | LDL-C↓ | HDL-C↑ | TG↓ | 副作用 | |
| HMG-CoA還元酵素阻害薬 | Choの合成阻害 →LDL受容体増加 |
○ | ○ | 発疹、胃不快感、肝障害、 筋肉痛、筋脱力、横紋筋融解症 | ||
| フィブラート系薬物 | VLDL産生抑制 →VLDL,IDL異化促進 |
○ | ○ | ○ | 単独で、横紋筋融解症 腹痛、下痢、嘔吐などの腹部症状、肝障害 | |
| ニコチン酸系薬 | VLDL分泌抑制 | ○ | ○ | ○ | 皮膚、特に顔面および上半身の紅潮、掻痒感 肝障害、胃腸障害、耐糖能の悪化、尿酸値上昇 | |
| 陰イオン交換樹脂系薬物 | 胆汁酸再吸収抑制 | ○ | 腹部膨満感、便秘、肝障害 | |||
| ビフェニル化合物 | Choの胆汁排泄促進 | ○ | 肝障害、胃腸障害、耐糖能の悪化、尿酸値上昇発疹 まれにQT延長にともなう不整脈 | |||
| EPA製剤 | VLDL産生抑制 →VLDL異化促進 |
○ | 胃部不快感、腹痛、下痢などの腹部症状 肝障害、出血傾向 | |||
| 分類 | 脂質代謝への影響 | 副作用 | ||
| LDL-C | TG | HDL-C | ||
| スタチン | ↓↓↓ | ↓ | ↑ | 横紋筋融解症、筋肉痛や脱力感などミオパチー様症状、肝障害、認知機能障害、空腹時血糖値およびHbA1c値の上昇、間質性肺炎など |
| 陰イオン交換樹脂 | ↓↓ | ↑ | ↑ | 消化器症状、脂溶性ビタミンの吸収障害。ジギタリス、ワルファリンとの併用ではそれら薬剤の薬効が減弱しうる。 |
| 小腸コレステロールトランスポーター阻害薬 | ↓↓ | ↓ | ↑ | 消化器症状、肝障害、CK上昇 |
| フィブラート | ↓ | ↓↓↓ | ↑↑ | 横紋筋融解症、肝障害など |
| ニコチン酸誘導体 | ↓ | ↓↓ | ↑ | 顔面潮紅や頭痛など(日本人では多いといわれている。少量から開始して漸増したり、アスピリンを併用することで副作用は回避可能なことがある) |
| プロブコール | ↓ | ー | ↓↓ | 可逆性のQT延長や消化器症状など |
| 多価不飽和脂肪酸 | ー | ↓ | ー | 消化器症状、出血傾向や発疹など |
| ↓↓↓：≦-25% ↓↓：-25%＜ ≦-20% ↓：-20%＜ ≦-10% ー：-10%＜ ≦10% ↑：10%＜ ≦20% ↑↑：20%＜ ≦30% | ||||
高脂血症治療薬一覧
「lipid-lowering drug」
- 関
- antilipemic agent、antilipemic drug、hypolipidemic、hypolipidemic agent、hypolipidemic drug、hypolipidemics、lipid-lowering agent
「hypolipidemic」
- adj.
- 脂質低下性の、脂質低下の
- n.
- 関
- antilipemic agent、antilipemic drug、hypolipidemic agent、hypolipidemic drug、hypolipidemics、lipid-lowering、lipid-lowering agent、lipid-lowering drug
「抗高脂血症剤」
- 英
- lipid-lowering drug、lipid-lowering agent、hypolipidemic drug
- 関
- 抗高脂血症薬、抗脂血剤、抗脂血薬、抗高脂血薬、抗高脂血剤、高脂血症薬、高脂血症治療薬
「antilipemic drug」
- 関
- antilipemic agent、hypolipidemic、hypolipidemic agent、hypolipidemic drug、hypolipidemics、lipid-lowering agent、lipid-lowering drug
「agent」
- n.
- 代行者、代理人。代理業者
- 政府職員、官吏
- ある後位をする人、ある作用をするもの。動員、動力因、作用因。(文法)動作主。科学的変化を起こさせるもの、薬品、～剤。病原体
- 関
- agonist、agonistic、attorney、delegate、drug、etiologic agent、fomes、fomites、mediator、pathogen、pathogenic、pharmaceutical preparation、vector、vehicle
「lowering」
- n.
- 低下、低減
「age」
- n.
- 年齢、歳
- v.
- 加齢する、熟成する
「lip」
- n.